Enveda Raises $311M at $2B Valuation to Push Nature-Derived AI Drugs Into Human Trials

Enveda has raised $311 million in new funding, a round that values the AI drug-discovery company at $2 billion, according to TechCrunch. The cash is earmarked for moving more of its nature-derived drug candidates into clinical trials, the stage where most biotech promises either hold up or fall apart.

The company's approach starts with molecules found in plants and other natural sources rather than with synthetic libraries cooked up in a lab. Enveda runs those compounds through machine-learning models trained to predict which ones might work as medicines, then tests the most promising hits. It is a bet that evolution has already done a lot of the hard chemistry, and that AI can sort through the noise faster than human researchers can alone.

Two programs are furthest along. One targets skin conditions, and the other aims to preserve weight loss after patients stop taking GLP-1 drugs such as Ozempic and Wegovy. That second effort lands in a market that has become one of the most lucrative in pharma, where a treatment that keeps the pounds off after someone quits a GLP-1 could reach millions of patients. Drugmakers have been racing to find ways to extend the benefits of those injections without requiring indefinite use.

The $2 billion valuation puts Enveda in the upper tier of AI-native biotechs, a group that has drawn heavy venture interest but has produced few approved medicines so far. Investors have been willing to fund discovery platforms on the premise that faster molecule identification will translate into more shots on goal, even though clinical failure rates in biotech remain high. The new capital gives Enveda more room to run multiple trials at once rather than picking a single lead candidate.

What the round does not settle is whether any of these compounds will clear the safety and efficacy bar in humans. That is the question every AI drug company eventually faces, and it is answered in clinics, not in funding announcements. Watch for trial readouts from the skin and weight-loss programs, and for whether Enveda names the specific compounds it plans to advance next.